Ublituximab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01-21 in 4mo
ESTIMATED |
READOUT
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regim
Phase 3 · Relapsing Multiple Sclerosis |
TG Therapeutics, Inc. | Ublituximab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-01
Sponsor-projected date — can change
|